It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Despite increasing insight into the genetics of infertility, the developmental disease processes remain unclear due to the lack of adequate experimental models. The advent of induced pluripotent stem cell (iPSC) technology has provided a unique tool for in vitro disease modeling enabling major advances in our understanding of developmental disease processes. We report the full characterization of complex genetic abnormalities in two infertile patients with either azoospermia or XX male syndrome and we identify genes of potential interest implicated in their infertility. Using the erythroblasts of both patients, we generated primed iPSCs and converted them into a naive-like pluripotent state. Naive-iPSCs were then differentiated into primordial germ-like cells (PGC-LCs). The expression of early PGC marker genes SOX17, CD-38, NANOS3, c-KIT, TFAP2C, and D2-40, confirmed progression towards the early germline stage. Our results demonstrate that iPSCs from two infertile patients with significant genetic abnormalities are capable of efficient production of PGCs. Such in vitro model of infertility will certainly help identifying causative factors leading to early germ cells development failure and provide a valuable tool to explore novel therapeutic strategies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 AP-HP, Université Paris-Saclay-Hôpital Antoine Béclère, Service d’Histologie, Embryologie et Cytogénétique, Clamart, France (GRID:grid.50550.35) (ISNI:0000 0001 2175 4109); Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France (GRID:grid.460789.4) (ISNI:0000 0004 4910 6535)
2 Université Paris-Saclay, Gustave Roussy Cancer Campus, Inserm U1287, Laboratoire Cellules Souches Hématopoïétiques et Hémopathies Myeloïdes, Villejuif, France (GRID:grid.14925.3b) (ISNI:0000 0001 2284 9388); Commissariat à l’Energie Atomique et Aux Énergies Alternatives, Institut de Biologie François Jacob, Laboratoire de Développement des Gonades, UMRE008 Stabilité Génétique Cellules Souches et Radiations, Fontenay-aux-Roses, France (GRID:grid.457334.2) (ISNI:0000 0001 0667 2738); Université de Paris, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602); Université Paris-Saclay, Orsay, France (GRID:grid.503243.3)
3 Commissariat à l’Energie Atomique et Aux Énergies Alternatives, Institut de Biologie François Jacob, Laboratoire de Développement des Gonades, UMRE008 Stabilité Génétique Cellules Souches et Radiations, Fontenay-aux-Roses, France (GRID:grid.457334.2) (ISNI:0000 0001 0667 2738); Université de Paris, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602); Université Paris-Saclay, Orsay, France (GRID:grid.503243.3)
4 AP-HP Sorbonne Université-La Pitié Salpêtrière, SiRIC Curamus, Paris, France (GRID:grid.50550.35) (ISNI:0000 0001 2175 4109)
5 Sup’Biotech/ Laboratoire CEA-IBFJ-SEPIA, Fontenay-aux-Roses, France (GRID:grid.50550.35)
6 Biologie de la Reproduction, AP-HP, Université Paris-Saclay - Hôpital Antoine Béclère, Clamart, France (GRID:grid.50550.35) (ISNI:0000 0001 2175 4109)
7 Université Paris-Saclay, INSERM UMR_S U1185, Faculté de Médecine Paris-Saclay, Le Kremlin Bicêtre, France (GRID:grid.460789.4) (ISNI:0000 0004 4910 6535); Hôpitaux Universitaires Paris Sud, AH-HP, CHU Bicêtre, Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, Paris, France (GRID:grid.413784.d) (ISNI:0000 0001 2181 7253)
8 Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine, Evry, France (GRID:grid.413784.d)
9 Sup’Biotech/ Laboratoire CEA-IBFJ-SEPIA, Fontenay-aux-Roses, France (GRID:grid.413784.d)
10 Hôpital Universitaire de Dijon, Département de Génétique Humaine, Dijon, France (GRID:grid.5613.1) (ISNI:0000 0001 2298 9313)
11 Université de Bourgogne et de Franche-Comté, Inserm UMR 1231 GAD, Faculté des Sciences de la Santé, Dijon, France (GRID:grid.5613.1) (ISNI:0000 0001 2298 9313)
12 Plateforme Bio-Informatique, IMAGINE Institute, Université Paris Descartes, Paris, France (GRID:grid.462336.6)
13 PhyMedExp, Université Montpellier, INSERM, CHU Montpellier, Montpellier, France (GRID:grid.157868.5) (ISNI:0000 0000 9961 060X)
14 IRMB, Université Montpellier, INSERM, CHU Montpellier, Montpellier, France (GRID:grid.157868.5) (ISNI:0000 0000 9961 060X)
15 AP-HP, Université Paris-Saclay-Hôpital Antoine Béclère, Service d’Histologie, Embryologie et Cytogénétique, Clamart, France (GRID:grid.50550.35) (ISNI:0000 0001 2175 4109); Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France (GRID:grid.460789.4) (ISNI:0000 0004 4910 6535); Commissariat à l’Energie Atomique et Aux Énergies Alternatives, Institut de Biologie François Jacob, Laboratoire de Développement des Gonades, UMRE008 Stabilité Génétique Cellules Souches et Radiations, Fontenay-aux-Roses, France (GRID:grid.457334.2) (ISNI:0000 0001 0667 2738)
16 Laboratoire des Mécanismes Moléculaires et Cellulaires des Maladies Hématologiques et leurs Implications Thérapeutiques; INSERM U 1163, Institut IMAGINE, Paris, France (GRID:grid.462336.6); CEA, Institut de Biologie François Jacob, Division des Thérapies Innovantes, Fontenay-aux-Roses, France (GRID:grid.457349.8) (ISNI:0000 0004 0623 0579)